LBI-0996
THERAPEUTIC AREA
SOLID TUMOR CANCER
Indications
Taxane resistant metastatic & Advanced Breast Cancer
REGULATORY PATHWAY
505(b)(2) with improved formulation
TARGET INDICATION
First-in-class immediate release nanomedicine microtubule inhibitor effective against taxane resistant & p-glycoprotein drug resistant cancers
CURRENT DEVELOPMENT STATUS
Active pre-clinical development
NEXT DEVELOPMENT PHASE
IND enabling study
TIME TO HUMAN BENEFIT
Human trials beginning in 1.5 to 2 years
IMMEDIATE FUNDING REQUIRED?
Yes, please inquire